



Toxicological Profile for *n*-Hexane

April 2025



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute-, intermediate-, and chronic-duration exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health due to acute-, intermediate-, and chronic-duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher M. Reh, Ph.D.
Associate Director

Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
April 2025	Final toxicological profile released
May 2024	Draft for public comment toxicological profile released
July 1999	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Obaid Faroon, D.V.M., Ph.D. (Lead)
Malcolm Williams, D.V.M., Ph.D.
Rae T. Benedict, Ph.D.
Melanie Buser, M.P.H.

Lisa Ingerman, Ph.D., D.A.B.T.
Jessica L. Myers, Ph.D.
Ramsey Hanna, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Sciences; NCEH, Division of Environmental Health Science and Practice; EPA, Office of Research and Development; EPA, Office of Water.

PEER REVIEWERS

1. Chunping Yang, Ph.D., PE (Ohio), Professor; School of Environmental Science and Engineering; Guangdong University of Petrochemical Technology; Maoming, Guangdong 525000, China and College of Environmental Science and Engineering; Hunan University; Changsha, Hunan 410082, China.
2. Marina Oktapodas Feiler, Ph.D., M.S.; Assistant Professor; Principal Investigator, Pediatric Environmental Health and Development Studies (PEDS) Laboratory; Department of Epidemiology and Environmental Health; School of Public Health and Health Professions; University at Buffalo; Buffalo, New York.
3. Hermann M. Bolt, Ph.D.; Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), Ardeystr. 67; 44579 Dortmund, Germany.

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	iv
CONTRIBUTORS & REVIEWERS	v
CONTENTS	vi
LIST OF FIGURES	viii
LIST OF TABLES	ix
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS	1
1.3 MINIMAL RISK LEVELS (MRLs)	5
CHAPTER 2. HEALTH EFFECTS	9
2.1 INTRODUCTION	9
2.2 DEATH	41
2.3 BODY WEIGHT	42
2.4 RESPIRATORY	43
2.5 CARDIOVASCULAR	44
2.6 GASTROINTESTINAL	44
2.7 HEMATOLOGICAL	44
2.8 MUSCULOSKELETAL	45
2.9 HEPATIC	45
2.10 RENAL	46
2.11 DERMAL	47
2.12 OCULAR	47
2.13 ENDOCRINE	48
2.14 IMMUNOLOGICAL	48
2.15 NEUROLOGICAL	49
2.16 REPRODUCTIVE	68
2.17 DEVELOPMENTAL	70
2.18 OTHER NONCANCER	71
2.19 CANCER	71
2.20 GENOTOXICITY	72
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	75
3.1 TOXICOKINETICS	75
3.1.1 Absorption	75
3.1.2 Distribution	77
3.1.3 Metabolism	78
3.1.4 Excretion	84
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	85
3.1.6 Animal-to-Human Extrapolations	92
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	92
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	95

3.3.1	Biomarkers of Exposure.....	96
3.3.2	Biomarkers of Effect.....	98
3.4	INTERACTIONS WITH OTHER CHEMICALS.....	99
CHAPTER 4.	CHEMICAL AND PHYSICAL INFORMATION.....	103
4.1	CHEMICAL IDENTITY.....	103
4.2	PHYSICAL AND CHEMICAL PROPERTIES.....	104
CHAPTER 5.	POTENTIAL FOR HUMAN EXPOSURE.....	106
5.1	OVERVIEW.....	106
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL.....	107
5.2.1	Production.....	107
5.2.2	Import/Export.....	110
5.2.3	Use.....	110
5.2.4	Disposal.....	112
5.3	RELEASES TO THE ENVIRONMENT.....	112
5.3.1	Air.....	114
5.3.2	Water.....	119
5.3.3	Soil.....	120
5.4	ENVIRONMENTAL FATE.....	120
5.4.1	Transport and Partitioning.....	120
5.4.2	Transformation and Degradation.....	121
5.5	LEVELS IN THE ENVIRONMENT.....	123
5.5.1	Air.....	125
5.5.2	Water.....	128
5.5.3	Sediment and Soil.....	129
5.5.4	Other Media.....	129
5.6	GENERAL POPULATION EXPOSURE.....	130
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES.....	131
CHAPTER 6.	ADEQUACY OF THE DATABASE.....	132
6.1	EXISTING INFORMATION ON HEALTH EFFECTS.....	132
6.2	IDENTIFICATION OF DATA NEEDS.....	134
6.3	ONGOING STUDIES.....	142
CHAPTER 7.	REGULATIONS AND GUIDELINES.....	143
CHAPTER 8.	REFERENCES.....	145
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS.....	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR <i>n</i> -HEXANE.....	B-1
APPENDIX C.	FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR <i>n</i> -HEXANE.....	C-1
APPENDIX D.	USER'S GUIDE.....	D-1
APPENDIX E.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	E-1
APPENDIX F.	GLOSSARY.....	F-1
APPENDIX G.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	G-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to <i>n</i> -Hexane	2
1-2. Health Effects Found in Animals Following Oral Exposure to <i>n</i> -Hexane	3
1-3. Summary of Sensitive Targets of <i>n</i> -Hexane – Inhalation.....	6
1-4. Summary of Sensitive Targets of <i>n</i> -Hexane – Oral.....	7
2-1. Overview of the Number of Studies Examining <i>n</i> -Hexane Health Effects	13
2-2. Levels of Significant Exposure to <i>n</i> -Hexane – Inhalation.....	27
2-3. Levels of Significant Exposure to <i>n</i> -Hexane – Oral.....	38
2-4. Reaction of 2,5-Hexanedione with Protein.....	67
3-1. Proposed Scheme for the Metabolism of <i>n</i> -Hexane	79
3-2. Perbellini et al. (1986, 1990b) Physiologically Based Pharmacokinetic Model.....	86
3-3. Fisher et al. (1997) Physiologically Based Pharmacokinetic Model	90
5-1. Number of NPL Sites with <i>n</i> -Hexane Contamination	106
5-2. Degradation of <i>n</i> -Hexane in Air by Free Radicals	122
5-3. Aerobic Biodegradation of <i>n</i> -Hexane in Sediment and Soil.....	123
6-1. Summary of Existing Health Effects Studies on <i>n</i> -Hexane by Route and Endpoint	133

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for <i>n</i> -Hexane.....	8
2-1. Levels of Significant Exposure to <i>n</i> -Hexane – Inhalation.....	14
2-2. Levels of Significant Exposure to <i>n</i> -Hexane – Oral.....	35
2-3. Levels of Significant Exposure to <i>n</i> -Hexane – Dermal.....	40
2-4. Results of Epidemiological Studies Evaluating Exposure to <i>n</i> -Hexane and Neurological Effects.....	50
2-5. Results of Rodent Studies Evaluating Inhalation Exposure to <i>n</i> -Hexane and Neurological Effects.....	59
2-6. Genotoxicity of <i>n</i> -Hexane <i>In Vitro</i>	72
2-7. Genotoxicity of <i>n</i> -Hexane <i>In Vivo</i>	73
3-1. Parameters Used in the Perbellini et al. (1986, 1990b) Physiologically Based Pharmacokinetic Model for <i>n</i> -Hexane.....	87
3-2. Parameters Used in the Fisher et al. (1997) Physiologically Based Pharmacokinetic Model for <i>n</i> -Hexane.....	90
4-1. Chemical Identity of <i>n</i> -Hexane.....	103
4-2. Physical and Chemical Properties of <i>n</i> -Hexane.....	104
5-1. Facilities that Produce, Process, or Use <i>n</i> -Hexane.....	108
5-2. Demand Patterns for Major Petroleum Products (1992).....	114
5-3. Releases to the Environment from Facilities that Produce, Process, or Use <i>n</i> -Hexane.....	115
5-4. Estimated Hexane Emitted in Pounds to the Environment According to EPA’s National Emission Inventory.....	118
5-5. Lowest Limit of Detection Based on Standards.....	124
5-6. Summary of Environmental Levels of <i>n</i> -Hexane.....	124
5-7. <i>n</i> -Hexane Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	125
5-8. Summary of Annual Concentration of <i>n</i> -Hexane (ppbv) Measured in Ambient Air at Locations Across the United States.....	128
5-9. Reasonable Maximum Exposure Daily Inhalation Dose in $\mu\text{g}/\text{kg}/\text{day}$ and Administered Dermal Dose of <i>n</i> -Hexane for the Target Person.....	130
7-1. Regulations and Guidelines Applicable to <i>n</i> -Hexane.....	143